SNV 001 - Synnovation Therapeutics
Alternative Names: SNV-001 - Synnovation TherapeuticsLatest Information Update: 19 Jun 2024
At a glance
- Originator Synnovation Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Apr 2023 Preclinical trials in Cancer in USA (PO), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)